

## Special Issue

# Development of New Cancer Treatment by Identifying and Targeting Pathogenic Abnormalities of Genes

### Message from the Guest Editor

Abnormalities of genes bring about changes in cellular functions, and thereby lead to the development of specific pathologies, in particular cancers. Therefore, the identification of such abnormalities provides a great advantage to the invention of new cancer treatment strategies.

Currently, abnormalities associated with cancers can be approached by small molecule drugs, monoclonal antibodies or gene therapy. However, it has been clarified that tumorigenic abnormalities of genes include not only mutations, but also aberrant alternative splicing, and uncontrolled gene expression by epigenetic factors and non-coding genes, most of which are not sufficiently understood yet.

This Special Issue calls for original articles, short reports, reviews, and perspectives covering novel tumorigenic abnormalities of coding and non-coding genes, and epigenetic factors that advance our current understanding of cancers. Besides, studies investigating novel small molecules, antibodies, and gene therapy targeting tumorigenic abnormalities are also welcome.

---

### Guest Editor

Dr. Hiroyuki Tsuchiya

Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan

---

### Deadline for manuscript submissions

closed (15 August 2021)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/54773](https://mdpi.com/si/54773)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))